{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:40:46Z","timestamp":1786984846224,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Hong Kong Research Grants Council"},{"DOI":"10.13039\/501100005407","name":"Food and Health Bureau of the Government of the Hong Kong Special Administrative Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Narcotics Division of the Security Bureau of The Government of the Hong Kong Special Administrative Region"},{"name":"The Hong Kong Research Grants Council"},{"DOI":"10.13039\/501100005407","name":"Food and Health Bureau of the Government of the Hong Kong Special Administrative Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.atherosclerosis.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T11:31:06Z","timestamp":1541849466000},"page":"174-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004\u20132015"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-198X","authenticated-orcid":false,"given":"Joseph E.","family":"Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon W.Y.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Wah","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib1","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7495","key":"10.1016\/j.atherosclerosis.2018.11.015_bib2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/bmj.38398.408032.8F","article-title":"Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials","volume":"330","author":"Wei","year":"2005","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib3","first-page":"1","article-title":"China cardiovascular diseases report 2015: a summary","volume":"14","author":"Chen","year":"2017","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib4","series-title":"Major causes of death [Internet]","author":"Government of the Hong Kong Special Administration Region, Department of Health","year":"2016"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin","volume":"24","author":"Naito","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2018.11.015_bib6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2018.11.015_bib7","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"J. Am. Med. Assoc."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2018.11.015_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS Thrive Collaborative Group","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib9","series-title":"Singapore: new recommendations for simvastatin use in Asians based on findings from the HPS2-THRIVE study [Internet]","author":"Government of the Hong Kong Special Administration Region, Department of Health","year":"2014"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.11.015_bib10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1253\/circj.CJ-11-1356","article-title":"Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: perspectives from the CREDO-Kyoto Registry Cohort-2","volume":"76","author":"Natsuaki","year":"2012","journal-title":"Circ. J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.11.015_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","article-title":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial","volume":"233","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.11.015_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12325-012-0017-9","article-title":"Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong","volume":"29","author":"Ambegaonkar","year":"2012","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.11.015_bib13","first-page":"395","article-title":"The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre","volume":"18","author":"Chan","year":"2012","journal-title":"Hong Kong Med. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12872-015-0117-y","article-title":"How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib15","unstructured":"Hong Kong Hospital Authority. Introduction [Internet]. [18 September 2018]. Available from: http:\/\/www.ha.org.hk\/visitor\/ha_visitor_index.asp?Content_ID=10008&Lang=ENG&Dimension=100&Parent_ID=10004."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2018.11.015_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2017.1363","article-title":"Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation","volume":"317","author":"Lau","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib17","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.11.015_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamainternmed.2016.1586","article-title":"Association between acute neuropsychiatric events and Helicobacter pylori therapy containing clarithromycin","volume":"176","author":"Wong","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib19","article-title":"Prenatal antidepressant use and risk of attention-deficit\/hyperactivity disorder in offspring: population based cohort study","volume":"357","author":"Man","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib20","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.11.015_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0149-2918(01)80074-6","article-title":"STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease","volume":"23","author":"Chung","year":"2001","journal-title":"Clin. Therapeut."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2018.11.015_bib22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/1087054714536047","article-title":"ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong","volume":"21","author":"Man","year":"2014","journal-title":"J. Atten. Disord."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.11.015_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014150","article-title":"10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database","volume":"7","author":"Hsieh","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.11.015_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00228-012-1328-0","article-title":"Statin use among older Finns stratified according to cardiovascular risk","volume":"69","author":"Upmeier","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamacardio.2016.4052","article-title":"Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Rodriguez","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2018.11.015_bib26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib27","series-title":"Thematic Household Survey Report - Report No. 63. Hong Kong","author":"Government of the Hong Kong Special Administration Region, Census and Statistics Department","year":"2017"},{"issue":"40","key":"10.1016\/j.atherosclerosis.2018.11.015_bib28","first-page":"1377","article-title":"Prevalence of coronary heart disease \u2014 United States, 2006\u20132010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR CDC Surveill Summ"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2018.11.015_bib29","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2018.11.015_bib30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice","volume":"24","author":"De Backer","year":"2003","journal-title":"Eur. Heart J."},{"issue":"2\u20133","key":"10.1016\/j.atherosclerosis.2018.11.015_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.healthpol.2012.08.008","article-title":"Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour","volume":"108","author":"Wallach Kildemoes","year":"2012","journal-title":"Health Pol."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CLEP.S104258","article-title":"Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using the Health Improvement Network primary care data","volume":"8","author":"O'Keeffe","year":"2016","journal-title":"Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.11.015_bib33","first-page":"429","article-title":"Developing primary care in Hong Kong: evidence into practice and the development of reference frameworks","volume":"18","author":"Griffiths","year":"2012","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib34","author":"Government of the Hong Kong Special Administration Region, Department of Health"},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib35","series-title":"Hong Kong reference framework for hypertension care for adults in primary care settings [Internet]","author":"Government of the Hong Kong Special Administration Region, Department of Health","year":"2018"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.11.015_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00228-006-0239-3","article-title":"Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003","volume":"63","author":"Deambrosis","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.11.015_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","article-title":"Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997\u20132003","volume":"60","author":"Walley","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib38","series-title":"FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury [Internet]","author":"Food and Drug Administation","year":"2011"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.11.015_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","article-title":"Primary prevention with statins in the elderly","volume":"71","author":"Mortensen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.11.015_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.atherosclerosis.2018.11.015_bib41","first-page":"362","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","author":"Ramos","year":"2018","journal-title":"BMJ"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:15:25Z","timestamp":1717186525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018314709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"alternative-id":["S0021915018314709"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004\u20132015","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}